in c tr temesgens legacy in c tr temesgen in washington dc
TRANSCRIPT
![Page 1: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/1.jpg)
IINNCCTRTRIINNCCTRTR Temesgen’s Legacy
![Page 2: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/2.jpg)
IINNCCTRTRIINNCCTRTRTemesgen in Washington DC
![Page 3: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/3.jpg)
IINNCCTRTRIINNCCTRTR
The Global Pattern of Childhood Cancer and
Advances made in High Income countries
Aziza Shad MDLombardi Comprehensive Cancer
CenterGeorgetown University Hospital
Washington DC, USAand
INCTR USA
![Page 4: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/4.jpg)
IINNCCTRTRIINNCCTRTR
2020 16-20 million new cancer cases each year ¾ of these in developing or resource-poor
countries
![Page 5: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/5.jpg)
IINNCCTRTRIINNCCTRTR
Developed and Developing Countries
Some Facts Developing countries
GNP per capita is 350$125 countries in the world
Developed countries GNP per capita > 25000$10 countries in the world
1/5 of the people in the highest income countries have 86% of the GNP
The bottom 1/5 have 1% of the GNP
![Page 6: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/6.jpg)
IINNCCTRTRIINNCCTRTR
Estimates of Population
0
1000
2000
3000
4000
5000
6000
7000
2002 2005 2010 2015 2020
Less Developed More Developed
Mill
ions
![Page 7: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/7.jpg)
IINNCCTRTRIINNCCTRTR
World Population Facts
In 1990, developing countries accounted for 78% of the world’s population and 86% of the world’s children below the age of 15
It is predicted that by 2030, 90% of the world’s children will live in developing countries
![Page 8: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/8.jpg)
IINNCCTRTRIINNCCTRTR
The Global Childhood Cancer Burden
0
50000
100000
150000
200000
0- 14 years 0- 19 years
More Developed Countries Less Developed Countries
![Page 9: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/9.jpg)
IINNCCTRTRIINNCCTRTR
Patterns of Childhood Cancer
40-50% of all pediatric cancer in the world is leukemia or lymphoma treatment largely chemotherapy, but needs
expertise
Pattern of cancer particularly different in Sub-Saharan Africa – high incidence of KS and BLKS largely HIV-related; preventable with
HAART
Brain tumors more common in more developed countries – higher incidence than lymphomasMay be partly due to failure to recognize
Retinoblastoma also probably higher incidence but lack of rural data misleading
![Page 10: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/10.jpg)
IINNCCTRTRIINNCCTRTR
Frequencies (%)
USA-WUSA-W BrazilBrazil UgandaUganda ZimbabwZimbabwee
LeukemiasLeukemias 3131 2828 66 2121
LymphomasLymphomas 1010 2121 2929 1111CNSCNS 2121 1313 11 1111SympatheticSympathetic 99 22 11 44RetinoblastomaRetinoblastoma 33 88 66 99RenalRenal 77 99 44 1515HepaticHepatic 22 00 11 22BoneBone 44 66 33 44Soft TissueSoft Tissue 77 44 4141 1818
![Page 11: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/11.jpg)
IINNCCTRTRIINNCCTRTR
USA Whites 83-92 (0-14 yrs)
31%
10%
21%
9%
3%
7%
2%
4%7%
3% 0%3%Leukemia
Lymphoma
CNS
Sympathetic NS
Retinoblastoma
Renal
Hepatic
Bone
Soft Tissue
Germ Cell
Carcinomas
OtherData from IARC IICC 1998
ALL 31%NHL 10%CNS 21%
14 per 100K
![Page 12: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/12.jpg)
IINNCCTRTRIINNCCTRTR
Uganda 92-95 (0-14 yrs)6%
29%
1%1%6%
4%1%3%
41%
1%3%4%
Leukemia
Lymphoma
CNS
Sympathetic NS
Retinoblastoma
Renal
Hepatic
Bone
Soft Tissue
Germ Cell
Carcinomas
OtherData from IARC IICC 1998
KS
>66%
KS or BL
18 per 100K
![Page 13: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/13.jpg)
IINNCCTRTRIINNCCTRTR
Pattern of Cancer in Ethiopia
There are no reliable statistics on the incidence of pediatric cancer in Ethiopia
With 42 million children under the age of 18 years, there could be as many as 5,628 new cases of pediatric cancer each year in Ethiopia.
![Page 14: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/14.jpg)
IINNCCTRTRIINNCCTRTR
Pattern of Cancer in Ethiopia
Leukemia Lymphoma Retinoblastoma Wilms tumor Bone and soft
tissue sarcomas
![Page 15: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/15.jpg)
IINNCCTRTRIINNCCTRTR
Childhood Cancer Survival
USA – approximately 12,400 children and adolescents < 20 years are diagnosed with cancer / yr7500 of these children are < 15 years of age
Dramatic progress in treatment of cancer in children in developed countries in the last 25 years
80% of children and adolescents diagnosed before the age of 20 are cured
![Page 16: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/16.jpg)
IINNCCTRTRIINNCCTRTR
Relative 5 yr Survival Rates (SEER) All Sites, M and F
77.5
0
20
40
60
80
100
1975 1980 1985 1990 1994
Age 0- 14 Age 0- 19
Perc
en
t
![Page 17: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/17.jpg)
IINNCCTRTRIINNCCTRTR
Five Year Survival Rates (SEER) 1992-8, 0-14 years
0 20 40 60 80 100
Wilm'Soft TissueNHLNeuroblastomaAMLALLHodgkin'sCNSBone
Percent
![Page 18: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/18.jpg)
IINNCCTRTRIINNCCTRTR
![Page 19: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/19.jpg)
IINNCCTRTRIINNCCTRTR
Childhood Cancer in Developing Countries – The Reality
Cure rate in developing countries currently <30%
Currently, only 20% of all children with cancer receive treatment sufficient to give them a chance for cure
![Page 20: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/20.jpg)
IINNCCTRTRIINNCCTRTR
Annual Deaths versus Cases
0
20000
40000
60000
80000
100000
120000
140000
MoreDeveloped
LessDeveloped
Deaths
Cases
NB. Data extrapolated from existing registries – the true situation is probably significantly worse
![Page 21: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/21.jpg)
IINNCCTRTRIINNCCTRTR
The Problem: a Vicious Cycle
Limited Resource
s
Many Patients With Advanced
Disease and Many Potential
Patients
LOW CAPACITY
POOR ACCESS
High Mortality Rate
Unmet need for terminal
care
![Page 22: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/22.jpg)
IINNCCTRTRIINNCCTRTR
Access to Care
![Page 23: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/23.jpg)
IINNCCTRTRIINNCCTRTR
poverty
lack of pediatric cancer units
lack of education and health knowledge
lack of transport and communication
infections
Problems faced by patients
anemia
![Page 24: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/24.jpg)
IINNCCTRTRIINNCCTRTR
Late Diagnoses
Courtesy, Dr Ashraf
![Page 25: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/25.jpg)
IINNCCTRTRIINNCCTRTR
Shortage of antibiotics
Few specialized units
ShortageOf cancer
drugs
Poor facilities
Doctors&
nurses
Problems faced By medicalpersonnel
patients
Poortraining
![Page 26: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/26.jpg)
IINNCCTRTRIINNCCTRTR
The Case to treat Pediatric Cancer
Many childhood cancers are highly curable if detected early
Treatment protocols have been adapted for use in low income countries that use readily available and inexpensive generic drugs.
![Page 27: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/27.jpg)
IINNCCTRTRIINNCCTRTR
The Solution: Build Capacity
Less Limited
Resources
Fewer Patients with More
Limited Disease and Fewer Potential Patients
Prevention
Education
Screening
GREATER CAPACITY
IMPROVED ACCESS
Lower Mortality Rate
Less need and
greater capacity
for terminal
care
![Page 28: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/28.jpg)
IINNCCTRTRIINNCCTRTR
The International Network for Cancer Treatment and Research
(INCTR) A not-for-profit, non-governmental
organization founded in 1998 by the UICC and the Institut Pasteur in Brussels
The National Cancer Institute, USA assists the INCTR by providing financial, technical and intellectual support
INCTR assists developing countries through a structured program of research collaboration, education and training
![Page 29: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/29.jpg)
IINNCCTRTRIINNCCTRTR
INCTR Mission Statement
INCTR is dedicated to helping build capacity for cancer treatment and research in countries in which such capacity is presently limited ……and to increase the quantity and quality of cancer research throughout the world.
Catalysis Concerted Effort Communication
Sustainability
![Page 30: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/30.jpg)
IINNCCTRTRIINNCCTRTR
The Goals
Cancer Cure
Cancer Prevention
Improvement in Quality of life
![Page 31: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/31.jpg)
IINNCCTRTRIINNCCTRTR
The Mechanism
Establishment of long term collaborative projects which will have an immediate impact on prevention or treatment
Associate such projects with education and training
Use information collected in the course of such projects as a foundation on which to build future endeavors
![Page 32: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/32.jpg)
IINNCCTRTRIINNCCTRTR
The Tool: Collaboration
Multiple networks: organizations, institutions, experts, supporters
![Page 33: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/33.jpg)
IINNCCTRTRIINNCCTRTR
INCTR’s Network
Offices and Branches
Collaborating Units
![Page 34: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/34.jpg)
IINNCCTRTRIINNCCTRTR
INCTR PEDIATRIC ONCOLOGY PROGRAM
Education and Training
Clinical Research
Palliative Care
![Page 35: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/35.jpg)
IINNCCTRTRIINNCCTRTR
PEDIATRIC CANCER IS OUR PRIORITY
![Page 36: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/36.jpg)
IINNCCTRTRIINNCCTRTR
EDUCATIONAL ACTIVITIES Pediatric Oncology Training
ProgramsEducational Workshops
Fellowship Program Visiting Experts Program Collaborative Efforts with other
Oncology Groups Development of Educational Material Telemedicine I-Path Program
![Page 37: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/37.jpg)
IINNCCTRTRIINNCCTRTR
TRAINING AND EDUCATION
Practical Management of Common Pediatric Cancers
Supportive Care ProgramGuidelines for management of
complications of treatment, blood transfusions, febrile neutropenia
![Page 38: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/38.jpg)
IINNCCTRTRIINNCCTRTR
CLINICAL TRAINING AND RESEARCH
![Page 39: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/39.jpg)
IINNCCTRTRIINNCCTRTR
Projects: Childhood Cancer
RETINOBLASTOMA
Early detection and treatment
OSTEOSARCOMA
Treatment of metastatic disease
LEUKEMIA (ALL)
Treatment and molecular studies
BURKITT’S LYMPHOMA
Treatment and molecular studies
PALLIATIVE CARE
![Page 40: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/40.jpg)
IINNCCTRTRIINNCCTRTR
MUMBAI
DELHI
CHENNAI
• CHENNAI
o DELHI
x MUMBAI
![Page 41: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/41.jpg)
IINNCCTRTRIINNCCTRTR
PALLIATIVE CARE
![Page 42: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/42.jpg)
IINNCCTRTRIINNCCTRTR
IMPORTANCE OF PEDIATRIC PALLIATIVE CARE
60% of children will die of their disease in the setting of low and middle income countries
![Page 43: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/43.jpg)
IINNCCTRTRIINNCCTRTR
PAX INITIATIVES Nepal (Kathmandu and Bhaktapur) India (Hyderabad) Tanzania (Dar es Salaam) Pakistan (early stages) Brazil Collaborative Efforts
INCTR and MECC
Educational initiatives3rd edition of Guidelines published
![Page 44: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/44.jpg)
IINNCCTRTRIINNCCTRTR
![Page 45: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/45.jpg)
IINNCCTRTRIINNCCTRTR
GOALS FOR ETHIOPIA
Train doctors to recognize and identify early stage cancers
Train a core group of pediatricians to treat patients using cost effective protocols designed for developing nations
Help establish a sufficient supply of essential chemotherapy drugs
Increase capacity to offer palliative care to patients with incurable disease
![Page 46: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/46.jpg)
IINNCCTRTRIINNCCTRTR
GOALS FOR ETHIOPIA
Twinning program with Georgetown University and INCTR for training and education
Curriculum for Fellowship Program in Pediatric Oncology and Palliative Care
Telemedicine education Center of Excellence in Pediatric
Cancer
![Page 47: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/47.jpg)
IINNCCTRTRIINNCCTRTR
Participation
![Page 48: IN C TR Temesgens Legacy IN C TR Temesgen in Washington DC](https://reader036.vdocuments.site/reader036/viewer/2022070305/551432ae5503466d1a8b50e8/html5/thumbnails/48.jpg)
IINNCCTRTRIINNCCTRTR
CURE FOR EVERY CHILD